S
ATYR

Sachetta’s aTyr Pharma ATYR Stock Holding History

Sachetta’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-830
Closed -$4.21K – 1140
2025
Q2 		$4.21K Hold
830
– – ﹤0.01% 630
2025
Q1 		$2.51K Buy
830
+430
+108% +$1.57K ﹤0.01% 731
2024
Q4 		$1.45K Buy
400
+250
+167% +$757 ﹤0.01% 910
2024
Q3 		$264 Hold
150
– – ﹤0.01% 1173
2024
Q2 		$297 Buy
+150
New +$261 ﹤0.01% 1194

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sachetta's ATYR Position: Q3 2025 in Review

Sachetta sold out of aTyr Pharma (ATYR) in Q3 2025, closing a stake of 830 shares — an estimated $4.21K sold.

Sachetta first reported a position in ATYR in Q2 2024 and held it in 5 quarters. The position peaked at $4.21K in Q2 2025. 103 funds tracked by Wall St. Rank hold ATYR as of Q3 2025.

  • Sachetta reported no remaining aTyr Pharma position as of Q3 2025 after selling out during the quarter.
  • Sachetta sold 830 aTyr Pharma shares in Q3 2025, an estimated $4.21K.
  • Sachetta first reported a position in aTyr Pharma in Q2 2024 and held it in 5 quarters.
  • Sachetta's aTyr Pharma position peaked at $4.21K in Q2 2025.
  • 103 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2025.

Based on Sachetta's 13F filing for Q3 2025, filed 24 Oct 2025.